We’re the leading resource for those affected by bleeding disorders. You can count on our organization to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.
FEATURED UPCOMING EVENTS:
-
NHF Colorado provides programming, education, and resources for individuals and families that are affected by genetic and chronic bleeding disorders. Our vision is to create an environment where you feel like part of a community, part of the solution, and empowered in your daily life through connection with others who can relate to you and your challenges. The chapter provides low cost and free opportunities throughout Colorado to create connections and allow a comprehensive understanding of available resources.
-
Check out NHF Colorado's wide-array of award-winning programs designed to meet the needs of the entire bleeding disorder community. Register for an event in your area today. Fundraisers and events help us raise awareness and generate crucial resources in support of the bleeding disorders community. Join us at our next event and see how you can get involved.
Find something to do. -
Our grassroots network is an integral part of our larger community. Team up with us and see what a huge difference a little bit of your time can make.
Get involved in building our bleeding disorder community by becoming a member, making a donation, or volunteering your time. NHF CO and the bleeding disorder community couldn’t do it without you!

BioMarin recently announced positive updates from its ongoing phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A. The trial currently includes 134 participants, all of whom have received a single dose of the therapy and have been observed for at least one year post treatment.
CSL Behring has announced a voluntary pharmacy level product recall of one batch of Mononine Coagulation Factor IX (Human), a plasma-derived product used to treat hemophilia B. CSL Behring’s notification states, “Patients can continue to use product they may have. Although the potential for safety risk to patients is considered low, it cannot be fully excluded.”
The affected batch is identified as: P100125501
The new joint clinical practice guidelines on the diagnosis and management of von Willebrand disease, developed by the American Society of Hematology (ASH), the International Society of Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) now have snapshot guides available in English, Spanish, and French.
The snapshots provide a high-level summary of both the diagnosis and management of VWD.
The new joint clinical practice guidelines on the diagnosis and management of von Willebrand disease, developed by the American Society of Hematology (ASH), the International Society of Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) now have snapshot guides available in English, Spanish, and French.
The snapshots provide a high-level summary of both the diagnosis and management of VWD.
“From Principles to Practice: Preparing for the Advent of Gene Therapy” represents the newest educational activity in Medscape’s series “Clinical Advances in Gene Therapy for Hemophilia.” Presented through a collaboration between Medscape and the National Hemophilia Foundation, the series includes various discussions relevant to the latest data on gene therapy as well as the practicalities associated with using gene therapy for hemophilia.
Subscribe to Our Newsletter
Fill in the fields below to receive our email newsletter.